{"id":95276,"date":"2026-03-28T12:22:50","date_gmt":"2026-03-28T06:52:50","guid":{"rendered":"https:\/\/vajiramandravi.com\/current-affairs\/?p=95276"},"modified":"2026-03-28T12:22:50","modified_gmt":"2026-03-28T06:52:50","slug":"ozempic-vs-olymviq","status":"publish","type":"post","link":"https:\/\/vajiramandravi.com\/current-affairs\/ozempic-vs-olymviq\/","title":{"rendered":"Ozempic vs Olymviq: Trademark Dispute Between Novo Nordisk and Dr Reddy\u2019s"},"content":{"rendered":"<h2><b>Ozempic vs Olymviq Latest News<\/b><\/h2>\n<ul>\n<li><span style=\"font-weight: 400;\">Novo Nordisk, the Danish pharma company behind the popular drug <\/span><b>Ozempic<\/b><span style=\"font-weight: 400;\"> (used for weight loss and diabetes), has been trying to protect its product from competition.\u00a0<\/span><\/li>\n<li><span style=\"font-weight: 400;\">After failing to win patent infringement cases against Indian generic companies, it filed a trademark case in the Delhi High Court against Dr Reddy\u2019s Laboratories.<\/span><\/li>\n<li><span style=\"font-weight: 400;\">Novo Nordisk argued that Dr Reddy\u2019s drug name \u201c<\/span><b>Olymviq\u201d<\/b><span style=\"font-weight: 400;\"> was too similar to \u201cOzempic\u201d and could cause confusion.\u00a0<\/span><\/li>\n<li><span style=\"font-weight: 400;\">Following this, Dr Reddy\u2019s agreed in court to stop further manufacturing and selling the drug under the name \u201cOlymviq\u201d for now.<\/span><\/li>\n<\/ul>\n<h2><b>Dr Reddy\u2019s Semaglutide Launch and Branding Strategy<\/b><\/h2>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Dr Reddy\u2019s Laboratories (DRL) launched its <\/span><b>semaglutide drug<\/b><span style=\"font-weight: 400;\"> under the brand name \u2018Obeda\u2019 on March 21, specifically for treating type-2 diabetes.<\/span>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"2\"><span style=\"font-weight: 400;\">Semaglutide is a medicine used to treat type 2 diabetes and is also prescribed for long-term weight management in people with obesity.<\/span><\/li>\n<\/ul>\n<\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">DRL had plans to market the same drug under two other names: Olymviq; Mashlo.\u00a0<\/span>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"2\"><span style=\"font-weight: 400;\">These were not disclosed during the initial announcement.<\/span><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<h3><b>Trademark Applications and Legal Developments<\/b><\/h3>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">DRL had first applied for the \u2018Olymviq\u2019 trademark in July last year, but it faced objections.\u00a0<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Later, it filed fresh trademark applications recently and also applied for the logo earlier in March 2026, indicating continued efforts to secure the brand name.<\/span><\/li>\n<\/ul>\n<h3><b>Unclear Positioning of Olymviq<\/b><\/h3>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">While Novo Nordisk markets Ozempic specifically for weight loss, DRL has not clearly disclosed the intended use of its Olymviq brand \u2014 whether for diabetes, weight loss, or another condition.\u00a0<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">The company has only stated that Olymviq is part of its broader semaglutide portfolio without further details.<\/span><\/li>\n<\/ul>\n<h2><b>Novo Nordisk\u2019s Trademark Argument Against Dr Reddy\u2019s<\/b><\/h2>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Novo Nordisk told the Delhi High Court that Dr Reddy\u2019s use of the name \u201cOlymviq\u201d infringes its \u201cOzempic\u201d trademark.\u00a0<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">It argued that \u201cOzempic\u201d is a unique, invented word, and \u201cOlymviq\u201d is deceptively similar in sound, potentially causing confusion and unfairly leveraging its brand.<\/span><\/li>\n<\/ul>\n<h2><b>Deceptively Similar Trademarks in Pharmaceuticals<\/b><\/h2>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">The Supreme Court laid down key principles to assess \u201cdeceptive similarity\u201d in drug trademarks in the <\/span><b>2001 Cadila Healthcare case<\/b><span style=\"font-weight: 400;\"> (<\/span><i><span style=\"font-weight: 400;\">Falcigo vs Falcitab<\/span><\/i><span style=\"font-weight: 400;\">).\u00a0<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">It rejected the argument that prescription-only drugs are less likely to cause confusion, noting that even small mistakes in medicines can have serious health consequences.<\/span><\/li>\n<\/ul>\n<h3><b>Stricter Standards for Drug Trademarks<\/b><\/h3>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Recognising that \u201cdrugs are poisons, not sweets,\u201d the Court set a lower threshold for confusion in pharmaceutical trademarks compared to other goods.\u00a0<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">It highlighted India\u2019s varied healthcare infrastructure and the risk of human error, making strict safeguards necessary.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">The Court established criteria such as <\/span><span style=\"font-weight: 400;\">phonetic similarity, visual resemblance, and similarity in the nature and use of drugs<\/span><span style=\"font-weight: 400;\"> to assess whether trademarks could cause confusion among consumers or healthcare providers.<\/span><\/li>\n<\/ul>\n<h3><b>Continued Judicial Application<\/b><\/h3>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Courts have consistently followed the Cadila ruling. In 2023, the Bombay High Court reiterated that even the slightest chance of confusion in medicinal products is sufficient to restrict the use of a similar trademark.<\/span><\/li>\n<\/ul>\n<h2><b>What is Permissible in Drug Trademarks<\/b><\/h2>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Under <\/span><b>Section 13 of the Trademarks Act<\/b><span style=\"font-weight: 400;\">, International Non-Proprietary Names (INNs)\u2014standard global names for drug ingredients\u2014cannot be monopolised, as they are generic and non-proprietary in nature.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Use of INN-Derived Names<\/b><span style=\"font-weight: 400;\"> &#8211; Pharmaceutical companies are allowed to derive brand names from INNs, provided the names are clearly distinguishable and not deceptively similar to existing trademarks.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Judicial Interpretation and Example<\/b><span style=\"font-weight: 400;\"> &#8211; In a 2022 Delhi High Court case (Letroz vs Letero), both derived from the INN \u201cLetrozole,\u201d the court ruled there was no deceptive similarity. It noted that specialised doctors, like oncologists, are unlikely to confuse such drugs despite similar prefixes.<\/span><\/li>\n<\/ul>\n<h2><b>Novo Nordisk\u2019s Fight to Protect Its Semaglutide Portfolio<\/b><\/h2>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Novo Nordisk\u2019s drugs <\/span><b>Ozempic<\/b><span style=\"font-weight: 400;\"> and <\/span><b>Wegovy<\/b><span style=\"font-weight: 400;\"> have driven strong global sales, but the company now faces declining growth due to the expiry of patent protections in several countries, including India.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">The company has filed multiple cases in India accusing generic manufacturers, including Dr Reddy\u2019s Laboratories (DRL), of patent infringement.\u00a0<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">However, it has seen limited success. Courts allowed DRL to manufacture and export generic semaglutide, and this decision was upheld by the Delhi High Court shortly before the patent expired.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Novo Nordisk is also facing legal challenges to the validity of its now-expired patent for injectable semaglutide, further weakening its position in India.<\/span>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"2\"><span style=\"font-weight: 400;\">With injectable patent protection expired, Novo Nordisk is now focusing on protecting its oral semaglutide drug, <\/span><b>Rybelsus<\/b><span style=\"font-weight: 400;\">, launched in India in December 2025 just months before patent expiry.<\/span><\/li>\n<\/ul>\n<\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">In a related case, DRL assured the Delhi High Court that its tablet formulation does not fall within the patented range of Rybelsus, as the composition differs in terms of salts used, potentially avoiding infringement.<\/span><\/li>\n<\/ul>\n<p><b>Source:<\/b> <strong><a href=\"https:\/\/indianexpress.com\/article\/explained\/explained-law\/ozempic-trademark-dispute-novo-nordisk-dr-reddys-delhi-hc-10603733\/\" target=\"_blank\" rel=\"nofollow noopener\">IE<\/a><\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Ozempic vs Olymviq trademark dispute highlights legal issues of deceptive similarity in pharma, as Novo Nordisk challenges Dr Reddy\u2019s branding in Indian courts.<\/p>\n","protected":false},"author":18,"featured_media":95280,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[18],"tags":[60,6422,22,59],"class_list":{"0":"post-95276","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-upsc-mains-current-affairs","8":"tag-mains-articles","9":"tag-ozempic-vs-olymviq","10":"tag-upsc-current-affairs","11":"tag-upsc-mains-current-affairs","12":"no-featured-image-padding"},"acf":[],"_links":{"self":[{"href":"https:\/\/vajiramandravi.com\/current-affairs\/wp-json\/wp\/v2\/posts\/95276","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vajiramandravi.com\/current-affairs\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/vajiramandravi.com\/current-affairs\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/vajiramandravi.com\/current-affairs\/wp-json\/wp\/v2\/users\/18"}],"replies":[{"embeddable":true,"href":"https:\/\/vajiramandravi.com\/current-affairs\/wp-json\/wp\/v2\/comments?post=95276"}],"version-history":[{"count":4,"href":"https:\/\/vajiramandravi.com\/current-affairs\/wp-json\/wp\/v2\/posts\/95276\/revisions"}],"predecessor-version":[{"id":95285,"href":"https:\/\/vajiramandravi.com\/current-affairs\/wp-json\/wp\/v2\/posts\/95276\/revisions\/95285"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/vajiramandravi.com\/current-affairs\/wp-json\/wp\/v2\/media\/95280"}],"wp:attachment":[{"href":"https:\/\/vajiramandravi.com\/current-affairs\/wp-json\/wp\/v2\/media?parent=95276"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/vajiramandravi.com\/current-affairs\/wp-json\/wp\/v2\/categories?post=95276"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vajiramandravi.com\/current-affairs\/wp-json\/wp\/v2\/tags?post=95276"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}